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Abstract Wnt/β-catenin pathway plays an important role
in initiation and progression of colorectal oncogenesis. The
aim of this study was to determine expression and
localization of E-cadherin, β-catenin and Wnt-1 proteins
in colorectal tumors. Expression of β-catenin, E-cadherin
and Wnt-1 was determined by immunohistochemistry on
advanced colorectal cancers. Abnormal expression of E-
cadherin, β-catenin, Wnt-1 was observed. Additionally, we
revealed correlations between levels of studied proteins and
histoclinical data. In multivariate analysis nuclear β-
catenin, higher carcinoembryonic antigen serum level
before treatment, female sex and tumor localized in colon
or rectum were independent unfavorable prognostic factors.
These findings support the hypothesis that Wnt/β-catenin
pathway plays an important role in advanced colorectal
carcinoma.
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Abbreviations
APC Adenomatous polyposis coli
βTrCP Ubiquitin ligase protein
CTNNB1 β-catenin gene
CDH1 E-cadherin gene
CEA Carcinoembryonic antigen
CI Confidence interval
CKI Casein kinase I
CRC Colorectal carcinoma
DFS Disease free-survival
FAP Familial adenomatous polyposis
FOLFIRI 5-fluorouracil leucovorin and irinotecan
FOLFOX4 5-fluorouracil leucovorin and oxaliplatin
GSK3β Glycogen synthase kinase 3β
K-RAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
HR Hazard ratio
MMP7 Metalloproteinase 7
OS Overall survival
R Spearman’s rank correlation coefficient
TCF/Lef T-cell factor/lymphoid enhancer factor
Wnt-1 Wingless-type MMTV integration site family
member 1
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Colorectal carcinoma (CRC) is one of the most common
human cancers. In 2008, 1233000 new CRC patients were
diagnosed worldwide and about 608000 deaths caused by
colorectal cancer were estimated making it the fourth most
common cause of death from cancer [1]. Five-year survival
for CRC patients amounts 54% in Europe, but in Poland it
is lower and amounts 38.8% [2]. Additionally, observed
five-year survival for patients with stage I is 74.0%, 66.5%
in patients with stage IIA disease, 73.1% in patients with
stage IIIA disease and only 5.7% in patients with stage IV
disease [3].
There are many factors influencing colorectal cancer
prognosis. According to College of American Pathologists
fundamental prognostic factors are: extent of tumor (pT
category), regional lymph node metastasis (pN category),
blood or lymphatic vessel invasion, residual tumor follow-
ing surgery and serum level elevation of carcinoembryonic
antigen (CEA) before treatment [4]. Other clinical and
pathological factors are also extensively studied, for
example histological type or microvessel density [5, 6].
Moreover, molecular markers are becoming to be important
variables that have an impact on CRC patient prognosis.
Variety of proteins are extensively explored in colorectal
carcinoma.
Particular interest of scientists is focused on a multi-
functional protein - β-catenin. Along with E-cadherin it
forms adherent junctions mediating epithelial cell adhesion
and it is the key protein in canonical Wnt signaling pathway
[7]. In the absence of Wnt ligands, β-catenin abundantly
occurs in adherent complexes, while its level in the
cytoplasm is very low. Free cytosolic β-catenin is phos-
phorylated in a complex formed by adenomatous polyposis
coli (APC), Axin, glycogen synthase kinase 3β (GSK3β)
and casein kinase I (CKI). Phosphorylated β-catenin is
ubiquitinated by ubiquitin ligase protein (βTrCP) and then
degraded in the proteasom. Binding one of the Wnt ligands
to the receptors FzD/LRP5/6 triggers signal inactivating the
degradation complex. Then β-catenin is stabilized and goes
to the nucleus, where it binds T-cell factor/lymphoid
enhancer factor (TCF/Lef) and activates gene expression.
Downstream target genes such as cyclin D1 [8], matrix
metalloproteinase 7 (MMP7) [9], c-Myc [10], survivin [11]
are responsible mainly for cell cycle and proliferation.
Therefore, Wnt/β-catenin pathway plays an important role
in initiation and progression of colorectal carcinoma [12].
Inactivating APC mutations as well as changes in β-catenin
gene (CTNNB1) often occur in colorectal tumors [13–15].
Additionally, changes ofβ-cateninandE-cadherinexpression
were observed in colorectal carcinoma [16–18].
The aim of this study was to determine the expression
and localization of β-catenin, E-cadherin and Wnt-1 in
colorectal tumors and to assess the impact of expression of
studied proteins on patients survival.
Material and Methods
Patients
Sixty-six unrelated patients with advanced colorectal
carcinoma were enrolled consecutively from CRC patients
attending Military Institute of the Health Services in
Warsaw for palliative care between 2003 and 2008. None
of them had a history of familial CRC. All patients were
treated according to the routine protocols for CRC patients.
All patient underwent radical resection of colorectal cancer
while metasectomy was not performed in these group of
patients according to guidelines of Polish Society of
Clinical Oncology [19]. The study was approved by Local
Ethical Committee at the Military Institute of the Health
Services, in Warsaw.
Patients characteristic is summarized in Table 1. Out of
66 cases, there were 22 women and 44 men. The mean age
was 71 years (range 59–83). Good performance status
(WHO 0–2 or Karnofsky ≥80%) was displayed by 59 pts
(86.4%) or 63 pts (95.5%), respectively. The majority
(81.8%) had T3 tumors and 46 pts (69.7%) had lymph
node involvement. All the patients had metastasis, most of
which was to the liver (57.6%). 25 (37.9%) patients have
been treated with adjuvant chemotherapy. Most of the
tumors were adenocarcinomas and they were well or
moderately differentiated (87.9% and 80.3%, respectively).
Immunohistochemistry
Formalin-fixed, paraffin-embedded primary tumors were
obtained from all patients. Tissue slides were routinely
stained with hematoxylin and eosin. For immunohisto-
chemistry analysis the slides were subjected to antigen
retrieval in Target Retrieval Solution, pH 9 (DAKO) with
PT Link (DAKO). Tissues were incubated with mouse
monoclonal antibody anti-β-catenin (dilution 1:100, clone
β-Catenin-1, DAKO), mouse monoclonal antibody anti-E-
cadherin (dilution 1:100, clone NCH-38, DAKO) or rabbit
polyclonal antibody anti-Wnt-1 (dilution 1:100, Thermo
Scientific). Negative controls were incubated with mouse or
rabbit IgGs (DAKO). Detection was done with EnVision
TM+system (DAKO). The expression was scored by two
independent observers who had no knowledge of the
clinical data. All membranous, cytoplasmic and nuclear
staining were evaluated. Staining was graded into four
groups: +++ strong, ++ moderate, + weak, 0 negative.
Tumors were regarded as immunopositive if 10% of tumor
cells showed immunoreactivity.
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A Spearman test for non-parametric variables was used to
assess correlation between histoclinical data and expression
of studied proteins. Overall survival (OS) was defined as
time elapsed between date of diagnosis and date of death or
the date of last follow-up. The end point of our analysis was
established on August 2008. Median and life tables were
computed using the product-limit estimate by the Kaplan
and Meier method and the log-rank test was employed to
assess the statistical significance, p values less than 0.05
were considered to indicate statistical significance. Univariate
and multivariate proportional-hazards models (Cox) were fitted
to the data to determine the importance of recognized
explanatoryvariables.Factorsthatweresignificantinunivariate
analysis and factors that showed a trend towards significance
were included in the multivariate model which evaluated
factors potentially influencing OS [i.e. age (<70 vs. >70 years),
Tstage, type of histology, and performance status]. Multivariate
analyses of overall survival were performed by Cox
proportional-hazard regression using the forward stepwise
method. Statistical calculation were performed using the
STATISTICA for Windows Version 7.0 software.
Results
Expression of E-cadherin, β-catenin and Wnt-1 in CRC
Normal tissue was available from 32 (48.5%) patients. In
all normal colonic epithelium E-cadherin and β-catenin
were present in the cell membrane with strong, continuous
staining. Adhesion proteins were not present in the
cytoplasm nor in the nuclei of normal epithelial cells
(Fig. 1 a, b). Wnt-1 was expressed in cytoplasm with strong
staining. No other localizations of Wnt-1 were found in
normal tissue (Fig. 1c).
In colorectal carcinoma, decreased expression and
changes of localization of studied proteins were observed
(Table 2,F i g .1d–f). Declined level of membrane E-
cadherin and β-catenin was observed in 31.8% (21/66)
and 22.7% (15/66) of patients, respectively. Abnormal
cytoplasmic E-cadherin was detected in 37.9% (25/66) of
cases. In comparison to the normal epithelium, aberrant
cytoplasmic and nuclear β-catenin was detected in 51.5%
(34/66) and 31.8% (21/66) of patients, respectively. We
observed that membrane E-cadherin was preserved in
those cells where membrane β-catenin was present. On
the other hand, in cancerous tissue cytoplasmic E-
cadherin colocalized with β-catenin. 60.6% (40/66) of
patients had decreased cytoplasmic Wnt-1 expression,
while 26 (39.4%) patients had tumor cells with normal,
strong Wnt-1 staining.
Table 1 Characteristics of patients (n=66)
Characteristics n=66
Age, years
Median (range) 71 (59–83)
Gender
Female 22 (33.3%)
Male 44 (66.6%)
WHO performance status before palliative treatment
0 18 (27.3%)
1 41 (62.1%)
2 5 (7.5%)
3 2 (3.0%)
Karnofsky performance status before palliative treatment
60% 1 (1.5%)
70% 2 (3.0%)
80% 5 (7.6%)
90% 43 (65.2%)
100% 15 (22.7%)
Histopathological type
Adenocarcionoma 58 (87.9%)
Mucinous adenocarcinoma 1 (1.5%)
Unclassified 7 (10.6%)
Use of adjuvant chemotherapy 25 (37.9%)
Elevated CEA level before palliative treatment(>5 μg/l) 37 (56.1%)
Histological differentiation
Well/moderately 53 (80.3%)
Poorly/undifferentiated 13 (19.7%)
Lymph node status
N0 20 (30.3%)
N1 19 (28.8%)
N2 19 (28.8%)
N3 8 (12.1%)
Primary tumor size
T2 3 (4.5%)
T3 54 (81.8%)
T4 9 (13.6%)
Primary tumor location
Colon 23 (34.8%)
Sigmoid colon 24 (36.4%)
Rectum 19 (28.8%)
Location of metastases
Liver 36 (57.6%)
Lungs 19 (28.8%)
Other 23 (34.8%)
Number of organs involved
1 37 (56.1%)
≥2 29 (43.9%)
Palliative chemotherapy first line
Capecitabine 26 (39.4%)
Irinotecan 5 (7.6%)
FOLFIRI 23 (34.8%)
FOLFOX4 12 (18.2%)
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Expression of E-cadherin, β-catenin and Wnt-1 did not
significantly correlate with tumor size, lymph node
involvement nor histopathological type of tumor. Analysis
of histoclinical data and expression of studied proteins
revealed association between tumor localization and presence
of β-catenin in nuclei. Cancer localized in rectum displayed
greaternuclearlocalizationofβ-cateninthantumorslocalized
insigmoid and colon (R 0.35; p=0.004). No other correlation
was found.
To investigate the association between expression of
studied proteins and survival, log-rank test was performed
(Table 3). There were no differences between patient
survival and age, sex, performance status, tumor size,
lymph node metastasis. As expected, elevated CEA level
before palliative treatment correlated with shorter survival.
Median survival of patients having elevated CEA level was
24.3 months, where median survival of patients having
CEA below 5 μg/l was 46.4 months (p=0.014). In addition,
patients with tumor localized in colon or rectum had worse
prognosis than patients with tumor localized in sigmoid
(20.9 vs. 47.9 months, p=0.028). Among analyzed proteins
only nuclear β-catenin was found to be statistically
associated with poor survival. Median survival of patients
with colorectal carcinoma displaying nuclear β-catenin was
two times shorter than CRC patients with normal β-catenin
(19.2 vs. 39.8; p=0.007) (Table 3, Fig. 2).
Factors that were significant in univariate analysis and
factors that showed a trend towards significance (p<0.1)
were included in the multivariate model which evaluated
factors potentially influencing OS (Table 4). We found that,
Fig. 1 Expression of E-cadherin, β-catenin and Wnt-1 in normal
colonic epithelium and in colorectal carcinoma. E-cadherin displayed
strong membranous immunoreactivity in normal epithelium (a), while
in cancer cells decrease of membranous and increase of cytoplasmic
E-cadherin was detected (d). High expression of β-catenin in the cell
membrane was found in normal cells (b). Week membranous,
moderate cytoplasmic and strong nuclear expression of β-catenin
was observed in tumor tissue (e). In normal epithelial cells high
cytoplasmic Wnt-1 expression was detected (c). In colorectal
carcinoma, there was weak Wnt-1 immunoreactivity (f)
Protein Membrane Cytoplasmic Nuclear
Normal Decreased Present Absent Present Absent
E-cadherin 45 (68.2%) 21 (31.8%) 25 (37.9%) 41 (62.1%) 0 0
β-catenin 51 (77.3%) 15 (22.7%) 34 (51.5%) 32 (48.5%) 21 (31.8%) 45 (68.2%)
Wnt-1 0 0 26 (39.4%) 40 (60.6%) 0 0
Table 2 Expression of
E-cadherin, β-catenin and
Wnt-1 in colorectal tumors
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CI 1.15–6.59; p=0.023), female sex (HR 2.73; 95% CI
1.32–5.68; p=0.023) and tumor localized in colon or
rectum (HR 3.11; 95% CI 1.42–6.82; p=0.005) were
independent prognostic factors for shortened survival.
Among studied proteins, nuclear β-catenin was confirmed
unfavorable prognostic factor (HR 2.48; 95% CI 1.30–4.74;
p=0.006).
Discussion
In this study we demonstrated that there are changes in the
expression and localization of β-catenin, E-cadherin and
Wnt-1 in advanced colorectal carcinoma. Additionally, we
revealed correlations between levels of studied proteins and
histoclinical data. We found that nuclear β-catenin, higher
carcinoembryonic antigen serum level before treatment,
Table 3 Univariate analysis of overall survival (log-rank test)
Covariate n (%) Median (months) p value
Age
≤70 years 41 (62.1%) 31.8 0.741
>70 years 25 (37.0%) 29.9
Gender
Female 22 (33.3%) 23.3 0.070
Male 44 (66.7%) 35.4
Histological differentiation level
Good/average 53 (80.3%) 32.6 0.307
Low/unknown 13 (19.7%) 16.5
Primary location
Sigmoid colon 25 (37.9%) 47.9 0.028
Colon/rectum 41 (62.1%) 20.9
WHO performance status
0 18 (27.3%) 49.5 0.140
1–2 48 (72.7%) 28.1
Karnofsky performance status
≤ 80 8 (12.1%) 21.4 0.624
>80 58 (67.9%) 32.0
Primary tumor size
T1-2 3 (4.6%) NA 0.530
T3-4 63 (95.4%) 31.8
Lymph node status
Cancer-free 20 (30.3%) 31.5 0.880
Involved 46 (69.7%) 30.1
Location of metastases
Liver 38 (57.6%) 24.7 0.068
Other 28 (42.4%) 47.9
Number of organs involved
1 37 (56.1%) 17.2 0.155
≥2 29 (43.9%) 37.0
Pretreatment CEA level (μg/l)
≤5 29 (43.9%) 46.4 0.014
>5 37 (56.1%) 24.3
E-cadherin membranous
normal 45 (68.2%) 30.9 0.963
decreased 21 (31.8%) 32.4
E-cadherin cytoplasmic
positive 25 (37.9%) 32.7 0.952
negative 41 (62.1%) 27.6
β-catenin membranous
normal 51 (77.3%) 31.7 0.649
decreased 15 (22.7%) 21.9
β-catenin cytoplasmic
positive 34 (51.5%) 27.4 0.707
negative 32 (48.5%) 39.9
β-catenin nuclear
positive 21 (68.2%) 19.2 0.007
negative 45 (31.8%) 39.8
Wnt-1
normal 26 (39.4%) 30.5 0.798
decreased 40 (60.6%) 30.2
NA not available
Fig. 2 Overall survival by nuclear β-catenin expression. The
continuous line: nuclear β-catenin positive (n=21). The dotted
line: nuclear β-catenin negative (n=45). The Kaplan-Meier, log rank
test, p=0.007
Table 4 Multivariate analysis of overall survival
Covariate Hazard ratio (95% CI) p value
Gender
Female vs. male 2.73 (1.32–5.68) 0.007
Pretreatment CEA level (μg/l)
>5 vs. ≤5 2.75 (1.15–6.59) 0.023
Primary location
Colon/rectum vs. sigmoid colon 3.11 (1.42–6.82) 0.005
Nuclear β-catenin
Positive vs. negative 2.48 (1.30–4.74) 0.006
Non significant correlations were not shown
β-catenin in Colorectal Carcinoma 959female sex and tumor localized in colon or rectum could be
independent unfavorable prognostic factors however the
influence of treatment on survival cannot be excluded.
β-catenin is a protein responsible for cellular adhesion
since it forms a complex with E-cadherin. On the other
hand, this protein is a key component of Wnt pathway
controlling proliferation and cell cycle. Disturbances in
both functions of β-catenin may affect colorectal tumor-
genesis. Changes of membrane β-catenin level may be
caused by the decrease of membrane E-cadherin. Our
results showing decreased level of membrane β-catenin
and membrane E-cadherin are concordant with numerous
earlier reports [16–18, 20, 21]. Additionally, we confirmed
previous data concerning detection of E-cadherin in the
cytoplasm of tumor cells [22, 23]. There are few studies
documenting that abnormal E-cadherin expression was
associated with poor prognosis [20, 22]. However, we did
not corroborate those findings.
Genetic alterations, transcriptional changes or protein
trafficking could disturb E-cadherin functions. Mutations of
CDH1 encoding E-cadherin are relatively rare in colorectal
carcinomas [24, 25], but are more frequent in gastric or
breast cancers [26, 27]. Furthermore Truant et al. showed
that mRNA level of E-cadherin in colon cancer is not
different than in normal tissue [28]. A possible explanation
for reduced level of E-cadherin is that proper formation of
cell-cell junctions could be disrupted by Src kinase.
Elevated Src expression disturbs E-cadherin regulation in
colon cancer cells [29]. However, detailed studies focused
on control of E-cadherin expression in colorectal carcinoma
are needed.
Decreased level of membrane E-cadherin could have
an impact on invasiveness of CRC cells. Tumor cell
release as a result of disruption of adherent junctions
plays a crucial role in metastasis. Expression of E-
cadherin observed in metastases varies. Some studies
showed that level of E-cadherin decreased in metastatic
liver as compared to primary tumor [21]. On the other
hand, expression of E-cadherin increased in metastatic
lymph nodes compared to primary tumor [30].
Furthermore, we detected β-catenin in cytoplasm and
nuclei of tumor cells. Recent studies showed that, in
advanced CRC, there was an increase of cellular and
nuclear level of β-catenin [16, 21, 31, 32]. Stabilization of
β-catenin in the cytoplasm, its transport to the nucleus and
activation of gene expression is enabled by Wingless
pathway. Wnt-1 is one of the ligands which trigger
signaling cascade. There are a few inconsistent studies
concerning Wnt-1 expression in colon, showing over-
expression or lack of expression of Wnt-1 in tumor when
compared to the normal colonic mucosa [33–35]. In our
study, we showed that in normal colon epithelium there is a
high expression of this ligand, whereas in the tumor tissues
there was a decrease of Wnt-1 expression. This result
suggests other mechanism of β-catenin accumulation than
Wnt-1 activation in analyzed cases of CRC.
Another plausible explanation of β-catenin stabiliza-
tion is occurrence of inactivating APC mutations. Most
colorectal carcinomas harbor mutations in APC or
CTNNB1 encoding β-catenin [13–15]. Inactivating muta-
tions in APC was found in familial adenomatous polyposis
(FAP) [36, 37], but they also occur in the sporadic CRC
[37, 38]. The most frequent are the mutations in β-catenin
binding domain [39]. Truncated APC is not able to bind
the β-catenin and leads to its accumulation which
provokes the activation of downstream target genes [15].
CTNNB1 mutations occur in the region coding amino
acids phosphorylated by GSK3β [14]. Thus mutated β-
catenin is rescued from phosphorylation and accumulates
in the nucleus.
We observed correlation between nuclear β-catenin and
tumors localized in rectal area. The association between β-
catenin and histoclinical data is disputed subject. There are
few inconsistent studies concerning correlation of nuclear
β-catenin with tumor localization. Our results differ from
those reported by other groups showing lack of association
between tumor localization and presence of nuclear β-
catenin in tumor cells [40, 41]. Instead we corroborate
previous observations that cancer localized in rectum
display higher level of nuclear β-catenin than tumors
localized in sigmoid and colon [42, 43].
Our search for prognostic factors for CRC resulted in
identification of tumor localization as unfavorable prognostic
factor. We found that tumors localized in colon or rectum are
associated with shorter survival, while tumors localized in
sigmoid area are correlated with prolonged survival. Our
results are concordant with Wray et al. who performed the
study on a large patient cohort (82 926 colon cancer cases)
and found an association between sigmoid tumors location
and decreased colorectal cancer-specific mortality, what is in
agreement with our study [44].
Another adverse prognostic factor for CRC identified in
our study was the presence of nuclear β-catenin. Although
some reports of nuclear β-catenin being a favorable
Table 5 Tumor location and nuclear β-catenin connection
Presence of nuclear β-catenin
Tumor location Correlation Multivariate analysis
(R Spearman
test; p value)
Hazard ratio
(95% CI); p value
Rectum 0.35; 0.004 3.11 (1.42–6.82); 0.005
Colon NS
Sigmoid NS
NS non significant
960 A. Stanczak et al.predictor of disease free survival (DFS) exist [32], our
finding is in agreement with a large body of previously
published evidence [17, 22, 30]. Such a discrepancy may
result from different localizations of tumors analyzed in
particular studies. We found that a high level of nuclear β-
catenin in tumors localized in rectum was paralleled by
poor clinical prognosis and that a low level of β-catenin in
nuclei was accompanied by prolonged survival in cases of
tumors localized in sigmoid but not in colon (Table 5).
These findings suggests that nuclear β-catenin could be an
adverse prognostic factor only for some tumor localization.
Moreover, low nuclear β-catenin level coincides with poor
clinical prognosis in patients with cancer localized in colon
what suggests existence of additional, yet unidentified
factors influencing survival.
The variety of physiological, anatomical and genetic
features of distinct sites of a large bowel results in different
tumor characteristics dependent on its localization. All of
these may influence clinical outcome. The existence of two
biologically distinct types of CRC - according to the tumor
location in the proximal or distal parts of a large bowel -
was proposed for the first time by Bufill [45]. In turn, Li et
al. suggested that there are three biological types of CRC
dependent on tumor localization in proximal colon, distal
colon and rectum [46]. Among genetic factors observed in
rectal cancers are: high incidence of chromosomal insta-
bility, Wnt/β-catenin activation and high p53 expression
[47, 48]. Conversely, microsatellite instability abundance
and K-RAS mutations are associated with colon tumors
[47, 48]. Diversity of molecular features of different CRC
types results in a complex array of possible prognostic
factors for colorectal tumors.
In our study, results of gender analysis may suggest
female sex as the unfavorable prognostic factor in colon
cancer. However, this observation is in conflict with other
reports showing no association between survival and
female sex [17, 32, 49]. Cautious interpretation of sex as
a prognostic factor in our study is required due to the lack
of sex-matched group and relatively small number of
patients analyzed.
In analyzed cases, higher CEA serum level before
treatment was associated with shorter survival what is in
agreement with observation that CEA is elevated in many
disorders, particularly in cancers including the colon,
rectum, breast and lung [50]. In the management of
colorectal carcinoma, CEA level is the most useful clinical
marker [50] and assessment of CEA concentration serves as
a screening test for CRC [51].
Numerous new markers for colorectal cancer are
discovered. Detailed list of factors measured in serum,
tissue or stool are described elsewhere [52]. Despite a
variety of analysis, there are only few prognostic factors
for advanced colorectal carcinoma [4] .F o rb e t t e rC R C
management more markers are needed. Although molec-
ular markers become more and more important in cancer
therapy, additional studies are needed to confirm their
usefulness.
Conclusion
In summary, our study demonstrated that in advanced CRC
there are disturbances in expression and localization of β-
catenin, E-cadherin and Wnt-1. We showed the link
between tumor localization and pattern of β-catenin
expression and additionally we reveled an association
between tumor localization and patient outcome. These
finding suggests that nuclear β-catenin could be an adverse
prognostic factor only for some tumor localization. A
limitation in our study was the number of patients and
controls included. Further investigations on a larger
population are needed. These finding support the hypothesis
that Wnt/β-catenin pathway plays an important role in
advanced colorectal carcinoma.
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